![Shao Lan Fu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shao Lan Fu
Chairman at PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD
Net worth: 351 M $ as of 31/05/2024
Shao Lan Fu active positions
Companies | Position | Start | End |
---|---|---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Chairman | 11/12/2023 | - |
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Chief Executive Officer | 01/05/1992 | - |
Chairman | 01/05/2009 | - |
Career history of Shao Lan Fu
Former positions of Shao Lan Fu
Companies | Position | Start | End |
---|---|---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Chief Executive Officer | 20/03/2015 | - |
Chairman | 20/03/2015 | - | |
Founder | 20/03/2015 | - |
Training of Shao Lan Fu
Chinese Academy of Sciences | Undergraduate Degree |
Cambridge Judge Business School | Graduate Degree |
Statistics
International
China | 4 |
Cayman Islands | 2 |
United Kingdom | 2 |
Operational
Chairman | 3 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Health Technology |
Private companies | 2 |
---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Health Technology |
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Health Technology |
- Stock Market
- Insiders
- Shao Lan Fu
- Experience